Regeneron Pharmaceuticals Stock Price and Value Analysis

Should you buy Regeneron Pharmaceuticals stock? (NasdaqGS:REGN). Let's see how it does in our automated value investing analysis system.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Regeneron Pharmaceuticals to reach your target.

Target type
AdvantagesDisadvantages
None.
  • This company has a low dividend yield.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is making money at a modest rate.
  • This company is less known than others.

Inside the REGN Numbers

REGN Price
(Regeneron Pharmaceuticals stock price per share)
$675.19
[?] REGN Fair Price
(based on intrinsic value)
$133.50
[?] REGN Safety Price (based on a variable margin of safety) $80.10
[?] PE Ratio versus Sector 18% lower than other Healthcare stocks
[?] PE Ratio versus Industry 71% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 0.74%
[?] Free Cash Flow Jitter 48%
[?] Dividend Yield 1% (tax impact)
Shares Shorted 3,494,420

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,494,420 shares shorted. With 97,667,436 shares available for purchase and an average trading volume over the past 10 trading days of 617,330, it would take at least 5.661 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Is Regeneron Pharmaceuticals Stock on Sale?

We believe that Regeneron Pharmaceuticals may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Regeneron Pharmaceuticals looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Advertisement supports free stock analysis content.

Should You Buy REGN Stock?

Does Regeneron Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: REGN

This example shows how we apply the Trendshare checklist to REGN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 675.19
    • Market cap: $71B
    • EPS: 41.12
  2. Step 2 — Valuation checks

    • P/E: 16.42
    • FCF yield: 0.7%
    • Date checked: Jul 22, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.